Security
AYTU · AYTU BIOPHARMA, INC
AYTUNASDAQCommon stockCurrentCIK 1385818Updated Sep 29, 2026
Name history
AYTU BIOSCIENCE, INC · through Mar 22, 2021Rosewind CORP · through Jun 8, 2015
AYTU price & chart
Loading TradingView…
NASDAQ:AYTU on TradingView ↗About the company
We are a pharmaceutical company focused on commercializing novel therapeutics. Our strategy is to become a leading pharmaceutical company that improves the lives of patients. We use a focused approach of in-licensing, acquiring, developing and commercializing novel prescription therapeutics in order to continue building our portfolio of revenue-generating products and leveraging our commercial team’s expertise to build leading brands within large therapeutic markets. Our primary focus is on commercializing innovative prescription products that address prevalent conditions, including attention deficit hyperactivity disorder (“ADHD”). We are focusing our efforts on accelerating the growth of our commercial business and achieving positive operating cash flows. To achieve these goals, we indefinitely suspended active development of our clinical development programs and have wound down and divested unprofitable operations. In conjunction with growing our prescription business we continue to pursue business development to identify novel products that complement our portfolio of prescription brands. To that end, we have agreed to terms to exclusively commercialize a novel antidepressant t…
In the news
No coverage from other publishers is available.
Recent filings
10-K filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
4 filing
Termination of a Material Definitive Agreement
Items 1.02
Show 5 more recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Results of Operations and Financial Condition · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders
Items 1.01, 2.02, 3.02, 3.03, 9.01
SCHEDULE 13G/A - filed by AWM Investment Company, Inc. regarding AYTU BIOPHARMA, INC
10-Q filing
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 105,007,000Source | 124,177,000Source | 118,095,000Source | 136,463,000Source |
| Property, Plant and Equipment, NetUSD | 385,000Source | 532,000Source | 693,000Source | 1,815,000Source |
| GoodwillUSD | — | — | — | 0Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 41,403,000Source | 42,201,000Source | 52,453,000Source | 58,970,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 26,308,000Source | 30,952,000Source | 20,006,000Source | 22,985,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 22,779,000Source | 31,155,000Source | 23,617,000Source | 28,937,000Source |
| Inventory, NetUSD | 6,860,000Source | 11,434,000Source | 12,633,000Source | 11,995,000Source |
| Assets, CurrentUSD | 61,761,000Source | 79,179,000Source | — | 72,832,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,814,000Source | 5,638,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 857,000Source | 1,061,000Source | 829,000Source | 2,054,000Source |
| Other Assets, NoncurrentUSD | 601,000Source | 1,204,000Source | 2,229,000Source | 792,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | — | — | — | 97,106,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 383,060,000Source | 352,500,000Source | 347,688,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -347,787,000Source | -333,535,000Source | -319,973,000Source | -304,129,000Source |
| Stockholders' Equity Attributable to ParentUSD | 35,274,000Source | 18,966,000Source | 27,716,000Source | 39,357,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | 343,485,000Source |
| Liabilities and EquityUSD | 105,007,000Source | 124,177,000Source | 118,095,000Source | 136,463,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 54,659,000Source | 63,064,000Source | 62,228,000Source | 69,015,000Source |
| Operating Lease, Liability, CurrentUSD | 221,000Source | 137,000Source | 712,000Source | 1,258,000Source |
| Accounts Payable, CurrentUSD | 11,284,000Source | 10,601,000Source | 10,440,000Source | — |
| Operating Lease, Liability, NoncurrentUSD | 853,000Source | 985,000Source | 577,000Source | 832,000Source |
| Other Liabilities, NoncurrentUSD | 4,774,000Source | 4,918,000Source | 4,529,000Source | 6,975,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 35,205,000Source | 38,164,000Source | 38,574,000Source | 46,799,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | — |
| Long-term Debt, Current MaturitiesUSD | 1,857,000Source | 1,857,000Source | 1,857,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 9,101,000Source | 10,895,000Source | 10,877,000Source | — |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -17,051,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 8,272,000Source | 8,815,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 691,000Source | 576,000Source | 2,913,000Source | 6,046,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -8,376,000Source | 7,629,000Source | -5,320,000Source | 7,153,000Source |
| Increase (Decrease) in InventoriesUSD | -2,387,000Source | -382,000Source | 2,908,000Source | 3,609,000Source |
| Increase (Decrease) in Accounts PayableUSD | -2,317,000Source | 287,000Source | -2,879,000Source | 2,384,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | 0Source | -126,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 3,281,000Source | -1,937,000Source | -1,388,000Source | -5,129,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -29,000Source | -2,560,000Source | -329,000Source | -117,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | 329,000Source | 112,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 29,000Source | 228,000Source | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -7,896,000Source | 15,443,000Source | -1,262,000Source | 8,871,000Source |
| Repayments of Long-term DebtUSD | 1,857,000Source | 1,857,000Source | 15,722,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -4,644,000Source | 10,946,000Source | -2,979,000Source | 3,625,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | 22,985,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,787,000Source | 2,822,000Source | 4,039,000Source | 3,812,000Source |
| Income Taxes Paid, NetUSD | 211,000Source | 1,419,000Source | 1,608,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 691,000Source | 576,000Source | 2,913,000Source | 6,046,000Source |
| Amortization of Deferred ChargesUSD | — | — | — | 6,100,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 113,000Source | 108,000Source | 597,000Source | 559,000Source |
| Amortization of Intangible AssetsUSD | 2,492,000Source | 3,683,000Source | 5,212,000Source | 4,788,000Source |
| DepreciationUSD | 100,000Source | 200,000Source | 900,000Source | 1,300,000Source |
| Depreciation, Amortization and Accretion, NetUSD | 3,930,000Source | 5,377,000Source | — | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | -4,734,000Source | -1,703,000Source | -4,004,000Source | 4,793,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 500,000Source | 0Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | — | — |
| General and Administrative ExpenseUSD | 19,272,000Source | 17,379,000Source | 22,514,000Source | 28,630,000Source |
| GoodwillUSD | — | — | — | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 8,300,000Source | 0Source | 5,600,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -14,252,000Source | -14,182,000Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 0Source | 620,000Source | — | — |
| Income Tax Expense (Benefit)USD | 21,000Source | 437,000Source | 1,768,000Source | 0Source |
| InterestExpenseNonoperatingUSD | 1,895,000Source | 3,703,000Source | 4,792,000Source | — |
| Inventory Write-downUSD | 2,187,000Source | 325,000Source | 2,270,000Source | 2,351,000Source |
| Net Income (Loss) Attributable to ParentUSD | -14,252,000Source | -13,562,000Source | -15,844,000Source | -17,051,000Source |
| Nonoperating Income (Expense)USD | — | — | — | 14,000Source |
| Operating ExpensesUSD | 45,133,000Source | 53,658,000Source | 59,840,000Source | 83,697,000Source |
| Other Nonoperating Income (Expense)USD | 713,000Source | -512,000Source | 568,000Source | -4,779,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 15,575,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 1,857,000Source | — | — |
| Restructuring CostsUSD | — | — | 3,095,000Source | — |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total RevenueUSD | 57,570,000Source | 66,382,000Source | 81,002,000Source | 107,399,000Source |
| Cost of RevenueUSD | 20,752,000Source | 20,551,000Source | 26,416,000Source | 40,767,000Source |
| Operating Income (Loss)USD | -8,315,000Source | -7,827,000Source | -5,254,000Source | -17,065,000Source |
| Other Nonoperating Income (Expense)USD | 713,000Source | -512,000Source | 568,000Source | -4,779,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -14,231,000Source | -13,745,000Source | -14,076,000Source | -17,051,000Source |
| Income Tax Expense (Benefit)USD | 21,000Source | 437,000Source | 1,768,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -14,252,000Source | -13,562,000Source | -15,844,000Source | -17,051,000Source |
| Earnings Per Share, BasicUSD per share | -1.16Source | -2.16Source | -2.86Source | -5.11Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | -5.11Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 12,318,817Source | 6,279,744Source | 5,537,957Source | 3,339,906Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 3,339,906Source |
| Interest Expense (non-operating)USD | 1,895,000Source | 3,703,000Source | 4,792,000Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 2,492,000Source | 3,683,000Source | 5,212,000Source | 4,788,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | 1,768,000Source | 126,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 7,456,000Source | 7,387,000Source |
| General and Administrative ExpenseUSD | 19,272,000Source | 17,379,000Source | 22,514,000Source | 28,630,000Source |
| Gross ProfitUSD | 36,818,000Source | 45,831,000Source | 54,586,000Source | 66,632,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -14,252,000Source | -14,182,000Source | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -1.16Source | -2.26Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 0Source | 620,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | — | 14,000Source |
| Operating ExpensesUSD | 45,133,000Source | 53,658,000Source | 59,840,000Source | 83,697,000Source |
| Research and Development ExpenseUSD | 0Source | 1,326,000Source | 2,791,000Source | 4,095,000Source |
| Restructuring CostsUSD | — | — | 3,095,000Source | — |
| Selling and Marketing ExpenseUSD | 23,369,000Source | 20,906,000Source | 26,958,000Source | 41,448,000Source |
Offerings
Registration 333-287728
- Deal price
- 1.5
- Offering price
- $1.500
- Ticker
- AYTU